RHY
RHYTHM BIO FPO [RHY]
Healthcare · ASX Small Cap
$0.1950 -4.9%
Updated 26 Mar 2026 · Scores refresh every scan
Score Breakdown
Technical61
Catalyst51
Sentiment50
Fundamental31
Momentum71
Risk Gate50
Get alerts when RHY's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Active Signals
Bullish Signals
- MACD momentum is losing steam
- Smart money may be accumulating — volume is flowing in even though price hasn't moved yet
- Volume-price trend says buyers are quietly accumulating — price hasn't caught up yet
- Trading above the 200-day average — the long-term trend is on your side
- Critical cash runway (1.1 quarters)
- Revenue in sharp decline (-49%)
- Small-cap ($20-100M)
- CANSLIM I: Institutional ownership (11%)
- Sentiment is mixed — no strong consensus either way
- Strong long-term momentum — up 231% over the past year (excluding last month)
- Excellent risk-adjusted returns — Sharpe of 1.6 means strong gains without wild swings
- The bigger volume days are the up days — volume-weighted momentum is positive (5.37%/day)
- RBA hiking (-3pts)
Risk Signals
- Piotroski F-Score weak (3/9, low-confidence approx)
- Not enough chatter to gauge sentiment — defaulting to neutral
- Revenue declining at -49% — the top line is shrinking
- Overseas neutral (-2pts, S&P500 neutral, VIX 25)
Ask Scout AI about RHY
3 free messages/day · Unlimited with Pro
Recent Catalysts
NONE First geneType Clinical Test Sale in South East Asia
NONE Application for quotation of securities - RHY
NONE Accelerating the Commercial Rollout of ColoSTAT
Recent ASX Announcements
| 2026-03-25 | First geneType Clinical Test Sale in South East Asia |
| 2026-03-20 | Application for quotation of securities - RHY |
| 2026-03-17 | Accelerating the Commercial Rollout of ColoSTAT |
| 2026-03-17 | Investor Webinar Presentation |
| 2026-03-13 | Application for quotation of securities - RHY |
Key Metrics
$64.4M
Market Cap
729K
Avg Volume
0.5x
Vol Ratio
$0.05 — $0.28
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-190.1%
ROE
N/A
Profit Margin
CANSLIM Analysis
| Factor | Rating | Detail | |
|---|---|---|---|
| C | Current EPS | fail | EPS Growth: 0% |
| A | Annual Earnings | fail | CAGR: 0% |
| N | New Highs / Catalysts | neutral | |
| S | Supply & Demand | neutral | Float: 71% |
| L | Leader vs Laggard | pass | RS: 10 |
| I | Institutional Sponsorship | pass | Inst: 10% |
| M | Market Direction | neutral | Neutral |
Sector: Healthcare
Ranked #68 of 117 · Sector avg: 46
View all Healthcare signals →Track RHY and 2,200+ ASX stocks
Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.
No credit card required